Study of PID23 injection for returning or hard-to-treat acute leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests an experimental injection called PID23 for people whose acute leukemia has come back or hasn't gone away. The goal is to see if it is safe and helps fight the leukemia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 3 and 75 years old.
- Your leukemia must have returned or not improved after standard treatment.
- At least 5% of the cells in your bone marrow must be leukemic blasts (immature cells).
- Your leukemia cells must show a marker called CD19, BCMA, or CD70 in lab tests.
- You must be physically able to care for yourself (ECOG performance status 0–2) and have a life expectancy of at least 3 months.
- Your heart, kidneys, liver, and lungs must be working well enough, and your blood counts must be at a certain level (you may have had transfusions or growth factors to help).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (called iNKT cells) that is designed to find and attack leukemia cells. It's for people whose leukemia has come back or hasn't gone away after standard treatments. The goal is to see if this therapy is safe and can help.
This trial tests a new cell treatment called IBR733 for people with acute myeloid leukemia (AML) that has come back or not responded to other treatments. The goal is to see if it is safe and helps fight the leukemia.
This trial tests a new treatment using special immune cells that target a protein called CD33 on leukemia cells. It's for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) who still have small amounts of cancer cells left after other treatments.
This trial tests an experimental drug, IDP-023, given alone or with antibody therapies for people with advanced blood cancers like multiple myeloma or non-Hodgkin lymphoma that have not responded to previous treatments. The goal is to see if it can shrink tumors or slow the disease.
This trial tests a new drug called PRG-2302 for people whose B-cell acute lymphoblastic leukemia (a type of blood cancer) has come back or not responded to standard treatments. The goal is to see if PRG-2302 is safe and can help control the disease.
This study tests an investigational drug called MEN2312 for people with acute myeloid leukemia (AML), a type of blood cancer, that has either come back or hasn't improved with treatment. The goal is to see if the drug can help control the disease.
Hear when a new Relapsed or Refractory Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.